PRESS RELEASE

Eugenia Litz is appointed as Vice President
Investor Relations of Ipsen

Paris (France), 01 June 2016 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Eugenia Litz as Vice President Investor Relations for the Ipsen Group, effective today. She will report to Aymeric Le Chatelier, Executive Vice President, Chief Financial Officer.

Eugenia Litz takes over Stéphane Durant des Aulnois nominated Finance Director Iberia. Eugenia will manage the Ipsen Group financial communication and build strong relations with investors and the financial community.

Eugenia holds a BA in Biological Sciences from Northwestern University Illinois and started her career as a clinical research associate, focusing on cardiovascular and gastrointestinal therapeutic areas. In 2001, she became a market research analyst for Frost & Sullivan and then equity research analyst at Avondale Partners and at Thomas Weisel Partners. In 2006, she joined BioMarin Pharmaceutical, a listed US biotech company in California to create the Investor Relations function. Since 2014, she was Director, Investor Relations for AstraZeneca PLC in London (UK).

About Ipsen
Ipsen is a global specialty-driven pharmaceutical group with total sales exceeding €1.4 billion in 2015. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in more than 30 countries. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its fields of expertise cover oncology, neurosciences and endocrinology. Ipsen's commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer and neuro-endocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis/Paris-Saclay, France; Slough/Oxford, UK; Cambridge, US). In 2015, R&D expenditure totaled close to €193 million. The Group has more than 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the “Service de Règlement Différé” (“SRD”). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.

Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group's future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group's expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact
that a promising product in early development phase or clinical trial may end up never being launched
on the market or reaching its commercial targets, notably for regulatory or competition reasons. The
Group must face or might face competition from generic products that might translate into a loss of
market share. Furthermore, the Research and Development process involves several stages each of
which involves the substantial risk that the Group may fail to achieve its objectives and be forced to
abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the
Group cannot be certain that favourable results obtained during pre-clinical trials will be confirmed
subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate
the safe and effective nature of the product concerned. There can be no guarantees a product will
receive the necessary regulatory approvals or that the product will prove to be commercially
successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual
results may differ materially from those set forth in the forward-looking statements. Other risks and
uncertainties include but are not limited to, general industry conditions and competition; general
economic factors, including interest rate and currency exchange rate fluctuations; the impact of
pharmaceutical industry regulation and health care legislation; global trends toward health care cost
containment; technological advances, new products and patents attained by competitors; challenges
inherent in new product development, including obtaining regulatory approval; the Group's ability to
accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of the Group’s patents
and other protections for innovative products; and the exposure to litigation, including patent litigation,
and/or regulatory actions. The Group also depends on third parties to develop and market some of its
products which could potentially generate substantial royalties; these partners could behave in such
ways which could cause damage to the Group’s activities and financial results. The Group cannot be
certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those
agreements. A default by any of the Group’s partners could generate lower revenues than expected.
Such situations could have a negative impact on the Group’s business, financial position or
performance. The Group expressly disclaims any obligation or undertaking to update or revise any
forward looking statements, targets or estimates contained in this press release to reflect any change
in events, conditions, assumptions or circumstances on which any such statements are based, unless
so required by applicable law. The Group’s business is subject to the risk factors outlined in its
registration documents filed with the French Autorité des Marchés Financiers.
The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s
2014 Registration Document available on its website (www.ipsen.com).

For further information:

Ipsen
Media
Didier Véron
Senior Vice-Président, Public Affairs
and Communication
Tel.: +33 (0)1 58 33 51 16
E-mail: didier.veron@ipsen.com

Financial Community
Eugenia Litz
Vice-President Investor Relations
Tel.: +44 (0) 1753 627721
E-mail: eugenia.litz@ipsen.com

Brigitte Le Guennec
Corporate External Communication Manager
Tel.: +33 (0)1 58 33 51 17
E-mail: brigitte.le.guennec@ipsen.com

Côme de la Tour du Pin
Investor Relations Executive
Tel.: +33 (0)1 58 33 53 31
E-mail: come.de.la.tour.du.pin@ipsen.com